Pacific Biosciences (PacBio) of California said today it has sold 10 Sequel ® System sequencers for an undisclosed price to Annoroad Gene Technology, a provider of genomics services that has disclosed its intent to build a “world’s leading genome center.” PacBio said the transaction will significantly expand the Single Molecule, Real-Time (SMRT ® ) sequencing capacity of Annoroad, a Beijing-based company specializing in applying next-generation genomics in human health and life science research. PacBio’s announcement confirms a December 7, 2017, Annoroad announcement that first disclosed the company’s purchase of the Sequel sequencers—part of its plans “to consolidate the construction of the world’s leading genome center,” including creating a multitechnology gene sequencing platform and a data center. The Sequel systems are expected to be installed at Annoroad facility “within the next several months” and are intended to enhance Annoroad’s large-scale genomic service capabilities across fields that include ...
Original Article: PacBio Sells Sequel System Sequencers to Annoroad